Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.49 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29939729 | 0.96 | TFPI (0.55) | TFPIRXFP1IL23R | |
| SCHEMBL29929055 | 0.92 | TFPI (0.54) | TFPIRXFP1PTH1RKEAP1 | |
| SCHEMBL29435830 | 0.92 | TFPI (0.56) | TFPIRXFP1PTH1R | |
| SCHEMBL31182934 | 0.91 | RXFP1 (0.58) | TFPIRXFP1PTH1R | |
| SCHEMBL30390186 | 0.91 | RXFP1 (0.57) | TFPIRXFP1PTH1R | |
| SCHEMBL31343254 | 0.89 | TFPI (0.53) | TFPIRXFP1PTH1RKEAP1 | |
| SCHEMBL30168700 | 0.89 | RXFP1 (0.51) | TFPIRXFP1IL23RPTH1R | |
| SCHEMBL31031482 | 0.89 | NPY4R (0.51) | TFPI | |
| SCHEMBL30389981 | 0.88 | RXFP1 (0.55) | TFPIRXFP1PTH1RKEAP1 | |
| SCHEMBL30262134 | 0.88 | TFPI (0.56) | TFPIRXFP1PTH1RKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915587-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2026-03-25 | — | — | EP | disclosed |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2026-01-01 | — | — | US | disclosed |
| EP-4647436-A2 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | Sapreme Technologies B.V. (NL) | 2025-11-12 | — | — | EP | disclosed |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-28 | — | — | US | disclosed |
| EP-3897735-B1 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | SAPREME TECH BV (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250302983-A1 | Saponin Conjugates | SAPREME TECHNOLOGIES B.V. (NL) | 2025-10-02 | — | — | US | disclosed |
| EP-4588523-A2 | IMPROVED CELL-TARGETING BINDING MOLECULE | Sapreme Technologies B.V. (NL) | 2025-07-23 | — | — | EP | disclosed |
| US-20250195682-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECHNOLOGIES B.V. (NL) | 2025-06-19 | — | — | US | disclosed |
| EP-4241847-B1 | IMPROVED CELL-TARGETING BINDING MOLECULE | SAPREME TECH BV (NL) | 2025-06-04 | — | — | EP | disclosed |
| EP-4374927-A2 | SAPONIN CONJUGATES | Sapreme Technologies B.V. (NL) | 2024-05-29 | — | — | EP | disclosed |
| EP-4223316-A2 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-08-09 | — | — | EP | disclosed |
| US-20230203153-A1 | ANTIBODIES SPECIFIC TO ABCB5 AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230173085-A1 | Saponin Conjugates | SAPREME TECHNOLOGIES B.V. (NL) | 2023-06-08 | — | — | US | disclosed |
| EP-4015003-B1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECH BV (NL) | 2023-05-10 | — | — | EP | disclosed |
| CN-116096753-A | Antibodies specific for ABCB5 and uses thereof | 儿童医学中心公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4142793-A1 | ANTIBODIES SPECIFIC TO ABCB5 AND USES THEREOF | Children's Medical Center Corporation (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220313834-A1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-10-06 | — | — | US | disclosed |
| US-20220218837-A1 | DRUG CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-07-14 | — | — | US | disclosed |
| EP-4015003-A1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | SAPREME TECHNOLOGIES B.V. (NL) | 2022-06-22 | — | — | EP | disclosed |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313834-A1 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | CD40, TNFSF10, IGSF11 | TFPI 2421/4885RXFP1 2059/4885IL23R 319/4885 |
| US-20250302983-A1 | Saponin Conjugates | EPCAM, CD47, SHBG | TFPI 2123/4885RXFP1 3659/4885IL23R 1068/4885 |
| US-20230173085-A1 | Saponin Conjugates | EPCAM, CD47, SHBG | TFPI 2123/4885RXFP1 3659/4885IL23R 1068/4885 |
| US-20260000783-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, FCGR3B | TFPI 1723/4885RXFP1 3267/4885IL23R 373/4885 |
| US-20220111066-A1 | ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW | EPCAM, CD47, EGFR | TFPI 1009/4885RXFP1 2944/4885IL23R 609/4885 |
| US-20220218837-A1 | DRUG CONJUGATE | OSTC, ADCY7, ADCY3 | TFPI 2481/4885RXFP1 3353/4885IL23R 1522/4885 |
| US-20230203153-A1 | ANTIBODIES SPECIFIC TO ABCB5 AND USES THEREOF | ABCB4, ABCB7, ABCD3 | TFPI 3907/4885RXFP1 4698/4885IL23R 3779/4885 |
| US-12453782-B2 | Antibody-oligonucleotide conjugate | CD40, FCGR1A, TNFSF10 | TFPI 2377/4885RXFP1 2114/4885IL23R 316/4885 |
| US-20250195682-A1 | IMPROVED CELL-TARGETING BINDING MOLECULE | EPCAM, CD47, CD74 | TFPI 2009/4885RXFP1 3789/4885IL23R 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.